Chronic Kidney Disease with Hyperphosphatemia

Addressing chronic kidney disease

Chronic kidney disease is the progressive decline of kidney function, which affects an estimated 37 million people in the U.S. The kidneys’ main job is to filter excess water and waste out of the blood through urine. They also balance salts and minerals like phosphorus — which circulate in the blood — and make red blood cells and hormones that regulate blood pressure. Once the kidneys have failed, dialysis is needed to filter and remove toxins from the blood. Without dialysis or a kidney transplant, kidney failure results in the accumulation of waste products that may ultimately cause death.

Hyperphosphatemia

Hyperphosphatemia is when a patient has an abnormally elevated level of phosphorous in their blood. It is a serious condition that affects the majority of chronic kidney patients on dialysis in the U.S. This happens because the kidneys are responsible for removing excess phosphorus from the body. As kidney function deteriorates, that phosphorous is not adequately eliminated from the body and patients experience elevated levels in their blood. The normal amount of phosphorus in the body ranges from 2.5mg/dL to 4.5mg/dL. The Kidney Disease Improving Global Outcomes (KDIGO) organization recommends chronic kidney disease patients on dialysis target serum phosphorus levels within the normal range.

Quiana’s Story

Living with CKD with Hyperphosphatemia

Hear from Quiana, as she shares her experience living with CKD and hyperphosphatemia, and what she wishes people knew about her diagnosis.

Learn More

Facts and Figures

37M

Kidney disease affects an estimated 37 million people in the U.S.

~90%

of those with kidney disease don‘t know they have it. Early chronic kidney disease has no signs or symptoms.

65+

Chronic kidney disease is more common in people aged 65 years, or older.

550K

There are more than 550,000 patients with chronic kidney disease on dialysis in the U.S.

80%

of chronic kidney disease patients on dialysis require prescription treatment for hyperphosphatemia.

~70%

of chronic kidney patients on dialysis treated with binders are unable to consistently maintain normal phosphorus levels over a six-month period.

Patient Advocacy Partners

We're proud to partner with organizations that raise awareness for those living with chronic kidney disease and support the patient journey:

Ardelyx created ArdelyxAssist™ an innovative, digital-forward, high-touch patient services program. ArdelyxAssist provides a broad range of access and affordability support for patients, with integration into medical office work processes and connectivity to patients and healthcare providers.

Call 617.675.ARDX (2739)

Interested in our clinical trials?

Medicines

Ardelyx was founded to discover, develop, and commercialize first-in-class, novel mechanism therapies that address significant unmet medical needs.

Learn More

Commitment to Patients

We believe in working closely with patients and their caregivers, listening to their needs and insights, and setting new standards in product innovation and community engagement.

Learn More

US-COR-0071